EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Using prostate‐specific membrane antigen positron‐emission tomography to guide prostate biopsies and stage men at high‐risk of prostate cancer

Yves J L Bodar iD, Liselotte M S Boevé, Pim J van Leeuwen, Phillippe C Baars, Jakko A Nieuwenhuijzen, Ernst P van Haarst, Jorg R Oddens, Maarten L Donswijk, Luigi A M J G van Riel iD, Matthijs J Scheltema, Dennie Meijer iD, N Harry Hendrikse und 2 weitere

BJU International · 2023-12 · 132 (6) · 705-712

DOI: 10.1111/bju.16167 ↗

Kurz gefasst

Fachartikel in der Zeitschrift BJU International, online erschienen am 13.09.2023. Verfasst von Yves J L Bodar und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Amsterdam University Medical Centres, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Prostate, Prostatic Neoplasms. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To assess whether a diagnostic pathway in which prostate‐specific membrane antigen (PSMA) positron‐emission tomography (PET)/computed tomography (CT) is used as a single imaging modality is feasible to guide targeted biopsy and to detect clinically significant prostate cancer (csPCa) in biopsy‐naïve men at high‐risk of disease. Patients and Methods A total of 60 men with a prostate‐specific antigen (PSA) level of 20–50 ng/mL underwent 18 F‐PSMA(DCFPyL)‐PET/CT prior to prostate biopsies in this prospective, non‐randomised cohort study. Magnetic resonance imaging (MRI) was not performed. Using a 12‐segment mapping model of the prostate, PSMA‐guided targeted biopsy was performed along with systematic biopsies. The detection rate of PCa and csPCa was assessed for combined systematic and targeted biopsy, and for targeted biopsy only. csPCa was defined as a prostate biopsy with an International Society of Uropathology (ISUP) Grade Group ≥2.

Results

Lesions suspicious for PCa in the prostate gland were observed on all PSMA‐PET/CTs. A total of 27/60 men (45%) already had metastatic disease on staging 18 F‐PSMA(DCFPyL)‐PET/CT. Combined PSMA‐guided targeted and systematic biopsies detected PCa in 56/60 (93.3%) patients, with 52 of them (92.9%) having csPCa. PSMA‐guided targeted biopsy, if performed as a single biopsy modality, identified PCa in 52/60 men (86.7%) and in 27/27 men (100%) men with metastases.

Conclusions

Using the PSMA‐driven single imaging modality pathway in biopsy‐naïve men at high‐risk of PCa, a substantial number of diagnostic MRI scans could be avoided while at the same time obtaining adequate targeting, staging, and detection of csPCa.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProstateProstatic NeoplasmsMaleHumansPositron Emission Tomography Computed TomographyCohort StudiesProspective StudiesProstate-Specific AntigenBiopsyPositron-Emission TomographyGallium Radioisotopes

Stichwörter der Autor:innen

PSMAdetectiondiagnosisprostate cancertarget biopsy

Substanzen

Prostate-Specific AntigenGallium Radioisotopes

Autor:innen und Institutionen

  • Department of Urology, Amsterdam University Medical Centres, Amsterdam, The Netherlands.
  • Department of Radiology and Nuclear medicine, Amsterdam University Medical Centres (VU University), Amsterdam, The Netherlands.
  • Prostate Cancer Network, Amsterdam, The Netherlands.
  • Department of Urology, Onze Lieve Vrouwe Gasthuis (OLVG), Amsterdam, The Netherlands.
  • Department of Urology, Netherlands Cancer Institute (NCI), Amsterdam, The Netherlands.
  • Department of Radiology and Nuclear Medicine, Onze Lieve Vrouwe Gasthuis (OLVG), Amsterdam, The Netherlands.

ORCID-Profile: Yves J L Bodar, Luigi A M J G van Riel, Dennie Meijer

Zitieren

APA

Bodar, Y. J. L., Boevé, L. M. S., van Leeuwen, P. J., Baars, P. C., Nieuwenhuijzen, J. A., van Haarst, E. P., Oddens, J. R., Donswijk, M. L., van Riel, L. A. M. J. G., Scheltema, M. J., Meijer, D., Hendrikse, N. H., Oprea-Lager, D. E., & Vis, A. N. (2023). Using prostate‐specific membrane antigen positron‐emission tomography to guide prostate biopsies and stage men at high‐risk of prostate cancer. BJU International, 132(6), 705-712. https://doi.org/10.1111/bju.16167

Vancouver

Bodar YJL, Boevé LMS, van Leeuwen PJ, Baars PC, Nieuwenhuijzen JA, van Haarst EP, et al. Using prostate‐specific membrane antigen positron‐emission tomography to guide prostate biopsies and stage men at high‐risk of prostate cancer. BJU International. 2023;132(6):705-712. doi:10.1111/bju.16167

BibTeX
@article{Bodar2023,
  author = {Bodar, Yves J L and Boevé, Liselotte M S and van Leeuwen, Pim J and Baars, Phillippe C and Nieuwenhuijzen, Jakko A and van Haarst, Ernst P and Oddens, Jorg R and Donswijk, Maarten L and van Riel, Luigi A M J G and Scheltema, Matthijs J and Meijer, Dennie and Hendrikse, N Harry and Oprea-Lager, Daniela E and Vis, André N},
  title = {Using prostate‐specific membrane antigen positron‐emission tomography to guide prostate biopsies and stage men at high‐risk of prostate cancer},
  journal = {BJU International},
  year = {2023},
  volume = {132},
  number = {6},
  pages = {705--712},
  doi = {10.1111/bju.16167}
}
Kostenlos starten →